Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: We recently have reported that human-derived gingival mesenchymal stem cells (GMSC) have strong capacity to suppress immune responses and T cell-mediated collagen-induced arthritis, however, it is unclear whether these cells can suppress human T cell-mediated diseases. In this project, we have developed a humanized animal model to investigate the interventional role of human GMSC in xeno-GVHD model, which is a best animal model to study human cell therapy prior to clinical trial.
Methods: Human gingival tissues were gained from discard samples from the patients who underwent dental operation. GMSC were isolated and grown from gingival tissues and cultured in α-MEM with 10%FBS for 3-6 generations. GMSC were harvested and added to human CD25 depleted CD3+ T cells for the co-culture with 0.025ng/ml anti-human CD3 antibody for in vitro suppression test. To determine the relative molecular mechanisms, various inhibitors and antagonists were added to the cultures. In vivo, sub-lethally irradiated NOD mice were given 2 × 107 peripheral blood mononuclear cell (PBMC) intravenously (IV) without (PBMC group) or with 2 × 106 GMSC (PBMC + GMSC group), while other NOD mice received 2 × 106 nTreg (PBMC + nTreg group) or 2×106 human fibroblast cell (PBMC + Fibroblast) for the controls. The levels of cytokines and IgG in mouse serum were measured by ELISA. Mice weight was measured twice a week and survival was monitored.
Results: We showed that GMSCs potently suppress the proliferation of human PBMC in vitro independent of cell contact. GMSC also suppress Th1, Th2 and Th17 cell differentiation. Co-transfer of human PBMC and GMSC significantly suppress IFN and IgG production, maintained weight and prolonged the mouse survival. In contrast, the adoptive transfer of human fibroblast cells did not suppress xeno-GVHD. Moreover, we demonstrated that GMSCs suppress xenogenic response of human PBMCs via CD39 and IDO signals.
Conclusion: Human GMSCs can suppress human immune responses and immune system-mediated diseases, offering a pre-clinical option to be used for modulating GVHD and other autoimmune diseases.
Disclosure:
S. G. Zheng,
None;
M. Chen,
None;
D. D. Chen,
None;
J. Gu,
None;
Y. Shen,
None.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/human-gingiva-derived-mesenchymal-stromal-cells-inhibit-graft-versus-host-disease-through-cd39-and-ido/